LEXINGTON, Mass., May 14, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced its support of the first global hereditary angioedema (HAE) awareness day, being held on May 16th, with a new Facebook page "Shire Supports HAE Awareness Day." Developed to help raise awareness of HAE, for every person who likes the Facebook page by May 16th, Shire will donate $1 to the U.S. Hereditary Angioedema Association (HAEA) up to $7,500. Visitors can learn more about HAE or share comments by clicking on the page's "Join the Discussion!" tab where new facts about this rare condition are posted each day. "Shire is dedicated to enabling people with life-altering conditions like HAE to lead better lives. This means not only providing much needed treatments for rare diseases, but also supporting awareness and education initiatives like HAE Awareness Day," said Hugh Cole, Global HAE Franchise Lead, Shire HGT. "I want to thank the 1,600 people who have already liked our Facebook page, and I encourage more people to visit the site and join in our effort. Liking the page is a fast and effective way to lend your support to HAE Awareness Day and the U.S. HAEA." HAE Awareness Day was initiated by the HAEi, the International Patient Organization for C1 Inhibitor Deficiency, along with support from its National Member Organizations including the U.S. HAEA. It is a global initiative to raise awareness of HAE among the general public and medical community with the aim of providing patients with better care, earlier and more accurate diagnosis. "This first annual global HAE awareness day will put a spotlight on HAE's impact on patients and their families," said Janet Long, Executive Vice President of the U.S. HAEA. "There remains a pressing need to broaden awareness of HAE so that people who suffer from recurring bouts of swelling are provided with a timely and accurate diagnosis and appropriate treatment. We are grateful for Shire's contribution which will support our longstanding commitment to education and personalized services for HAE patients across the United States." Founded and staffed by HAE patients and caregivers, the U.S. HAEA is a 4500 member, non-profit patient advocacy organization dedicated to serving persons with hereditary swelling conditions caused by C1 Inhibitor Deficiency and other undetermined causes. The US HAEA's fundamental goal is to improve the lives of HAE patients and their families by providing a support network and a wide range of services including: individualized patient support, physician referrals, authoritative and readily accessible disease-related information, and clinical research aimed at finding a cure.